Log In
Print
BCIQ
Print
Print this Print this
 

danoprevir (ASC08, ITMN-191, RG7227) (formerly R7227)

Also known as: formerly ITMN B

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionHCV NS3/4A protease inhibitor
Molecular Target HCV NS3/4A protease complex
Mechanism of ActionViral protease inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat HCV genotype 1 infection; Treat HCV genotype 1 infection in patients who failed previous therapy; Treat HCV infection
Regulatory Designation
Partner Ascletis Pharmaceuticals Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today